Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Zacks News
CVS Health (CVS) Q1 Earnings Surpass Estimates, EPS View Cut
by Zacks Equity Research
CVS Health's (CVS) robust sales growth across all three operating segments drives top-line results.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.
Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust
by Zacks Equity Research
Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Despite a year-over-year decrease, Omnicell's (OMCL) first-quarter revenues and earnings exceed the top end of the previously announced outlook amid an uncertain macroeconomic environment.
Zimmer Biomet (ZBH) Q1 Earnings Beat Estimates, View Raised
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic's (HOLX) Q2 revenues.
IDEXX (IDXX) Q1 Earnings Beat Estimates, Margins Increase
by Zacks Equity Research
Continued solid demand for veterinary services and record global premium instrument placements drive IDEXX's (IDXX) Q1 revenues.
Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.
Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study
by Kinjel Shah
Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.
Integer Holdings (ITGR) Q1 Earnings, Revenues Beat Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust Medical and Non-Medical sales, besides strength in all the product lines.
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.
Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised
by Zacks Equity Research
Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.
AbbVie (ABBV) Q1 Earnings Beat, Skyrizi Sales Underperform
by Zacks Equity Research
AbbVie's (ABBV) first-quarter 2023 earnings and sales beat estimates. However, share price dives as some key drugs miss sales estimates.
Accuray (ARAY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.
AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales
by Zacks Equity Research
AstraZeneca (AZN) beats first-quarter estimates for earnings while missing the same for sales. The company reaffirms its 2023 guidance.
Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.
Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal second-quarter top line on the back of robust Medical Device revenues.
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms Guidance
by Zacks Equity Research
Strength in the VITAS and Roto-Rooter branches contributes to Chemed's (CHE) first-quarter top line.
Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
GSK Beats on Q1 Earnings, Lags Sales, Reaffirms 2023 Outlook
by Zacks Equity Research
Though GSK's revenues benefit from strong growth across all segments, the declining COVID-19 antibody sales do not bode well. Management reaffirms its 2023 guidance.
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q1 performance will likely reflect declining sales of Humira following the loss of exclusivity. Sales of Rinvoq and Skyrizi are expected to partially offset this fall.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates
by Ekta Bagri
We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.
Is ALPS O'Shares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSA